Medicare Transaction Facilitator
-
340B, Caught my eye, CMMI, Drug Prices, FDA, Generics, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Medicare Transaction Facilitator, Obesity, Reference PricingAMP is WAC — 1/9/26
Read more: AMP is WAC — 1/9/26Something is bugging me this week. Okay, lots of things are bugging me this week, but the one that is relevant to this newsletter is the STAT News headline that implied it is awesome to be a pharmaceutical executive in 2026. This week, there were reports of more than 25,000 layoffs in pharma last year.…
-
340B, Caught my eye, Drug Prices, Generics, Medicare Part D, Medicare Transaction Facilitator, Orphan Drugs, Reference Pricing, VaccinesAMP is WAC — 09/04/25
Read more: AMP is WAC — 09/04/25A Monday off is always a double win, longer weekend and shorter week. Caught My Eye Made me Laugh. 340B can be funny. Go PhRMA. Zebras, Not Unicorns. The Food and Drug Administration announced a new rare disease approval framework. While it acknowledges the challenge of rare disease, it is unclear if the new framework…
-
340B, Caught my eye, COVID, Drug Prices, Medicaid, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, VaccinesAMP is WAC — 05/30/25
Read more: AMP is WAC — 05/30/25I do love a Monday off. It somehow feels like an a double-treat – you get the Monday off and the week flies by. Yes we had to cram more meetings and work into the shorter week but totally worth it. Caught my Eye Processed Over. This week the Secretary of Health and Human Services,…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Drug shortages, Employers, Inflation Reduction Act, Medicare Negotiation, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Preventative, Reference Pricing
Caught my eye — 5/16/25
Read more: Caught my eye — 5/16/25This week I’ve repeatedly spoken to groups about the President’s Executive Order (EO) on Most Favored Nation (MFN) pricing and I feel a little vulnerable. I am often “authentic” in my explanations. I recognize that to many people I seem biased on a lot of issues but, in my defense, I find most politics maddening…
-
340B, Caught my eye, Drug Prices, Inflation Reduction Act, Medicare Negotiation, Medicare Transaction Facilitator, Medicare Transaction Facilitator, Pharmacy Benefit Managers, State-based Reform, UncategorizedCaught my eye — 4/4/25
Read more: Caught my eye — 4/4/25Mom and Pop Going Broke. The economics of pharmacies are fascinating. Like did you know they usually lose money on brand-name drugs? A pharmacy benefit manager (PBM) law in Montana would help those pharmacies get closer to at least breaking even and make sure they get dispensing fees. I thought this KFF piece was a…
-
Affordable Care Act, Caught my eye, Cell and Gene, CMMI, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Pharmacy Benefit ManagersCaught my eye — 2/7/25
Read more: Caught my eye — 2/7/25In the DC area, with many family, friends and neighbors working for the federal government, these last few weeks have felt downright crappy. Furloughs, contracts being upended, fear about what’s next — all for people who love their jobs serving the public. It isn’t a fork in the road, it feels like a game of…
-
340B, Caught my eye, Drug Prices, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Medicare Transaction FacilitatorCaught my eye — 10/18/24
Read more: Caught my eye — 10/18/24Order (Not) Ready. The National Community Pharmacists Association surveyed just under 500 independent pharmacy owners and the results are really interesting. Almost ¾ had not signed 2025 Part D pharmacy contracts as of about a month ago. Of those that dispense GLP-1 agonists, 96% lose money on them; it makes sense why 59% are thinking…
-
Caught my eye — 10/3/24
Read more: Caught my eye — 10/3/24For most drugs, it is not IF but WHEN they will be negotiated by Medicare so if you thought you could ignore guidance coming out this week, you were wrong. Everyone on the pharma side needs to be thinking of how the Inflation Reduction Act impacts them, even if you’re early on in the pipeline…
-
340B, Caught my eye, Drug Prices, Generics, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction FacilitatorCaught my eye — 8/23/24
Read more: Caught my eye — 8/23/24It’s an Inflation Reduction Act (IRA) hangover kind of week. Last week the first Medicare negotiated prices for 2026 were announced and this week is the “what does this mean?” week with everyone catching up and chiming in. What I wrote last week stands but if you want another review, Health Affairs/KFF has you covered.…
-
No Time for Patience
Read more: No Time for PatienceToday I’m doing a presentation for patient advocates on the Initial Price Applicability Year (IPAY) Guidance 2027 that the Centers for Medicare & Medicaid Services put out a few weeks ago. I thought you might enjoy the overview as well. Long story short – the guidance is focused on the Medicare negotiation process for 2027.…
Latest news
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
- AMP is WAC — 2/6/26
Categories
- 340B (62)
- Affordable Care Act (21)
- Alzheimer's (10)
- Biosimilars (31)
- Caught my eye (101)
- Cell and Gene (5)
- Chevron Deference (2)
- CMMI (26)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (6)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (67)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (76)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (26)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)